Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells
Christian D. Fingas(Essen University Hospital), Gregory J. Gores(Mayo Clinic in Arizona), Alphonse E. Sirica(Virginia Commonwealth University), Sophie C. Cazanave(Virginia Commonwealth University), Justin L. Mott(University of Nebraska Medical Center), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Nathan W. Werneburg(Mayo Clinic), Steven F. Bronk(Mayo Clinic), Maria Eugenia Guicciardi(University of Minnesota Rochester)
Cited by 153
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k